{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T12:18:23Z","timestamp":1648642703842},"reference-count":0,"publisher":"Ideggyogyaszati Szemle Journal","issue":"5-6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ideggyogy Sz"],"published-print":{"date-parts":[[2015]]},"DOI":"10.18071\/isz.68.0155","type":"journal-article","created":{"date-parts":[[2015,6,10]],"date-time":"2015-06-10T15:44:38Z","timestamp":1433951078000},"page":"155-164","source":"Crossref","is-referenced-by-count":1,"title":["Alemtuzumab: benefits and challenges of new therapy in Multiple Sclerosis"],"prefix":"10.18071","volume":"68","author":[{"given":"Zsolt","family":"Ill\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Sejbaek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T\u00fcnde","family":"Cs\u00e9p\u00e1ny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7411","container-title":["Ideggy\u00f3gy\u00e1szati Szemle"],"original-title":["Alemtuzumab: egy \u00faj ter\u00e1pia el\u0151nyei \u00e9s kih\u00edv\u00e1sai sclerosis multiplexben"],"deposited":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T22:22:40Z","timestamp":1614810160000},"score":1,"resource":{"primary":{"URL":"https:\/\/elitmed.hu\/en\/publications\/clinical-neuroscience\/alemtuzumab-benefits-and-challenges-of-new-therapy-in-multiple-sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":0,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.18071\/isz.68.0155","relation":{},"ISSN":["0019-1442"],"issn-type":[{"value":"0019-1442","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}